BR9608683A - Preparação para diagnóstico de síndrome metabólica e doenças incluindo a síndrome - Google Patents

Preparação para diagnóstico de síndrome metabólica e doenças incluindo a síndrome

Info

Publication number
BR9608683A
BR9608683A BR9608683-1A BR9608683A BR9608683A BR 9608683 A BR9608683 A BR 9608683A BR 9608683 A BR9608683 A BR 9608683A BR 9608683 A BR9608683 A BR 9608683A
Authority
BR
Brazil
Prior art keywords
syndrome
diagnosis
metabolic syndrome
preparation
cortisol
Prior art date
Application number
BR9608683-1A
Other languages
English (en)
Inventor
Per Marin
Original Assignee
Cortendo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortendo Ab filed Critical Cortendo Ab
Publication of BR9608683A publication Critical patent/BR9608683A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Combined Controls Of Internal Combustion Engines (AREA)

Abstract

"PREPARAçãO PARA DIAGNóTICO DE SìNDROME METABóLICA E DOENçAS INCLUINDO A SìNDROME". Uso de agonistas de cortisol para a preparação de um sistema para diagnose de síndrome metabólica e de condições relacionadas como gordura na cintura, resistência a insulina incluindo risco aumentado de desenvolver diabetes senil, isto é, diabete tipo II, altas taxas de gorduras no sangue e alta pressão sang³ínea, em cujo sistema a dose de agonista de cortisol ocorre em um intervalo onde a diferença é obtida no efeito inibitório da autoprodução do cortisol em indivíduos sofrendo de síndrome metabólica, comparado aos valores normais.
BR9608683-1A 1995-05-30 1996-05-30 Preparação para diagnóstico de síndrome metabólica e doenças incluindo a síndrome BR9608683A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9501991A SE505391C2 (sv) 1995-05-30 1995-05-30 Användning av kortisol-agonister för framställning av ett system för diagnostisering av det metabola syndromet
PCT/SE1996/000708 WO1996038179A1 (en) 1995-05-30 1996-05-30 Preparation for diagnostic of the metabolic syndrome and diseases including the syndrome

Publications (1)

Publication Number Publication Date
BR9608683A true BR9608683A (pt) 1999-12-07

Family

ID=20398470

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9608683-1A BR9608683A (pt) 1995-05-30 1996-05-30 Preparação para diagnóstico de síndrome metabólica e doenças incluindo a síndrome

Country Status (16)

Country Link
US (1) US6410339B1 (pt)
EP (1) EP0835138B1 (pt)
JP (1) JPH11505850A (pt)
CN (1) CN1078479C (pt)
AT (1) ATE235258T1 (pt)
AU (1) AU716671B2 (pt)
BR (1) BR9608683A (pt)
CA (1) CA2222215A1 (pt)
DE (1) DE69626982T2 (pt)
DK (1) DK0835138T3 (pt)
ES (1) ES2189872T3 (pt)
NO (1) NO319829B1 (pt)
PT (1) PT835138E (pt)
RU (1) RU2171471C2 (pt)
SE (1) SE505391C2 (pt)
WO (1) WO1996038179A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217505B2 (en) * 1998-02-26 2007-05-15 Cortendo Ab Method for determining whether condition is symptom of metabolic syndrome
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
DE102004034640A1 (de) 2004-07-16 2006-02-16 Institut für Molekular- und Systemmedizin Verfahren zur systemischen Biokorrektur eines Organismus
US20090117660A1 (en) * 2005-04-30 2009-05-07 Oakville Hong Kong Co., Limited Devices and methods for sample collection and analysis
WO2008057160A2 (en) * 2006-10-06 2008-05-15 Nestec S.A. Compositions and multiplex assays for measuring biological mediators of physiological health
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
RU2444298C1 (ru) * 2010-07-15 2012-03-10 Учреждение Российской академии медицинских наук Научный центр клинической и экспериментальной медицины Сибирского отделения РАМН (НЦКЭМ СО РАМН) Способ диагностики метаболического синдрома
CN105973881A (zh) * 2016-04-27 2016-09-28 樊福好 一种检测机体活度的溶液及检测方法

Also Published As

Publication number Publication date
NO975492L (no) 1998-01-27
NO319829B1 (no) 2005-09-19
DK0835138T3 (da) 2003-07-21
EP0835138A1 (en) 1998-04-15
DE69626982D1 (de) 2003-04-30
SE505391C2 (sv) 1997-08-18
RU2171471C2 (ru) 2001-07-27
NO975492D0 (no) 1997-11-28
AU716671B2 (en) 2000-03-02
CN1185743A (zh) 1998-06-24
SE9501991L (sv) 1996-12-01
AU5917396A (en) 1996-12-18
MX9709234A (es) 1998-10-31
JPH11505850A (ja) 1999-05-25
SE9501991D0 (sv) 1995-05-30
WO1996038179A1 (en) 1996-12-05
ATE235258T1 (de) 2003-04-15
DE69626982T2 (de) 2004-03-04
ES2189872T3 (es) 2003-07-16
CA2222215A1 (en) 1996-12-05
EP0835138B1 (en) 2003-03-26
CN1078479C (zh) 2002-01-30
US6410339B1 (en) 2002-06-25
PT835138E (pt) 2003-08-29

Similar Documents

Publication Publication Date Title
BR9608683A (pt) Preparação para diagnóstico de síndrome metabólica e doenças incluindo a síndrome
Kassan et al. Clinical manifestations and early diagnosis of Sjögren syndrome
Parish et al. Relationship of metabolic syndrome and obstructive sleep apnea
Wing et al. Exercise in a behavioural weight control programme for obese patients with type 2 (non-insulin-dependent) diabetes
Yokoe et al. Intermittent hypoxia reverses the diurnal glucose rhythm and causes pancreatic β‐cell replication in mice
Vgontzas et al. Sleep deprivation effects on the activity of the hypothalamic–pituitary–adrenal and growth axes: potential clinical implications
Halbreich et al. Hypothalamo-pituitary-adrenal activity in endogenously depressed post-traumatic stress disorder patients
Van Cauter et al. Rapid phase advance of the 24-h melatonin profile in response to afternoon dark exposure
RU97121292A (ru) Препарат для диагностики метаболического синдрома и заболеваний, включающих в себя данный синдром
Parker et al. Lowering dialysate temperature improves sleep and alters nocturnal skin temperature in patients on chronic hemodialysis
Xie et al. SIRT1 activation ameliorates aldara-induced psoriasiform phenotype and histology in mice
Svane-Knudsen Sudden “spontaneous” lesion of aural function
Schmidt Binge eating and binge eating disorder.
Muchnik et al. Effect of emotional stress on hearing
Alinezhad‐Namaghi et al. Association of time‐restricted feeding, arterial age, and arterial stiffness in adults with metabolic syndrome
DE602004022968D1 (de) Ie behandlung mti insulinsensibilisatoren
Del Seppia et al. Evidence in hypertensive rats of hypotensive effect after mandibular extension
LAN et al. Tetrodotoxin intoxication in a uraemic patient
Wang et al. Serum 25‐Hydroxyvitamin D Levels in Type 2 Diabetes Patients in North China: Seasonality and the Association between Vitamin D Status and Glycosylated Hemoglobin Levels
Hotchkiss et al. Evaluation of a nonhuman primate model to study circadian rhythms of calcium metabolism
Hezarkhani et al. Comparison of glycemic excursion in patients with new onset type 2 diabetes mellitus before and after treatment with repaglinide
Babu et al. Drug excretion in saliva-A review
Westaway et al. Management of diabetes mellitus in outpatient facilities is achieving poor results
Ettema et al. IX. Health effects of exposure to noise, commentary on a research program
Yanagishita et al. Construction of novel in vitro epithelioid cell granuloma model from mouse macrophage cell line

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
EG Technical examination (opinion): publication of technical examination (opinion)
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements